Newborn screening for cystic fibrosis

Current Opinion in Pediatrics

Volumn 15, Issue 3, 2003, Pages 309-315

  Wagener, Jeffrey S ^a,b   Sontag, Marci K ^a   Accurso, Frank J ^a  

^a Children's Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE CONTROL; EARLY DIAGNOSIS; GENETIC ANALYSIS; GENETIC SCREENING; HEALTH CARE SYSTEM; HUMAN; MORTALITY; NEWBORN CARE; NEWBORN SCREENING; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

CYSTIC FIBROSIS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PROGNOSIS; SURVIVAL RATE;

EID: 0038290157     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200306000-00015     Document Type: Review

References (116)

1. Marshall E: Medicine. Fast technology drives new world of newborn screening. Science 2001, 294:2272-2274. • This article describes the new technique of tandem mass spectrometry for neonatal screening.
2. Comeau AM, Eaton RB: Successes of newborn screening programs. Science 2002, 295:44-45.
3. Rhoades E, King P: Public health explores expanding newborn screening for cystic fibrosis, congenital adrenal hyperplasia, and medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD). J Okla State Med Assoc 2001, 94:129-132.
4. Wagener JS, Farrell PM, Corey M: A debate on why my state (province) should or should not conduct newborn screening for cystic fibrosis. Pediatr Pulmonol 2001, 32:385-396. • This is a comprehensive discussion of the pros and cons surrounding CF screening.
5. Young SS, Kharrazi M, Pearl M, et al.: Cystic fibrosis screening in newborns: results from existing programs. Curr Opin Pulm Med 2001, 7:427-433.
6. Merelle ME, Nagelkerke AF, Lees CM, et al.: Newborn screening for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev 2001, 3:CD001402.
7. Farrell PM, Kosorok MR, Laxova A, et al.: Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997, 337:963-969. •• This pivotal article presents the results of the first controlled study on the efficacy of newborn screening for CF.
8. Doull IJ, Ryley HC, Weller P, et al.: Cystic fibrosis-related deaths in infancy and the effect of newborn screening. Pediatr Pulmonol 2001, 31:363-366. • This report describes results from the second large controlled study of CF newborn screening. Nearly 500,000 infants were included and mortality related to CF was seen only in the control group or in patients identified because of meconium ileus.
9. Robinson P: Cystic fibrosis. Thorax 2001, 56:237-241.
10. Siret D, Branger B, Storni V, et al.: Does neonatal screening of cystic fibrosis affect outcome? Comparative study of two cohorts in Brittany and Loire. Atlantique with follow-up after ten years. Arch Pediatr 2000, 7:1154-1162.
11. Wunderlich P, Stopsack M, Paul KD, et al.: [Mucoviscidosis screening of newborn infants in the Dresden district. Results from 1 June 1996 to 31 March 2000]. Dtsch Med Wochenschr 2000, 125:1356-1360.
12. Farrell PM: Improving the health of patients with cystic fibrosis through newborn screening. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr 2000, 47:79-115. Farrell reviews the extensive data and experience from the Wisconsin newborn CF screening program.
13. Dezateux C: Screening newborn infants for cystic fibrosis. J Med Screen 2001, 8:57-58.
14. Grosse SD, Khoury MJ, Hannon et al.: Early diagnosis of cystic fibrosis. Pediatrics 2001, 107:1492.
15. Dudding T, Wilcken B, Burgess B, et al.: Neonatal screening for cystic fibrosis. Lancet 2000, 356:1930.
16. Merelle ME, Schouten JP, Gerritsen J, et al.: Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001, 18:306-315. This important report shows how newborn screening is not sufficient to assure improved care for infants with CF. A well-organized, specialty care network is needed to maximize the benefits of screening.
17. Assael BM, Castellani C, Ocampo MB, et al.: Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol 2002, 156:397-401.
18. Mastella G, Zanolla L, Castellani C, et al.: Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology 2001, 1:531-537.
19. Quan JM, Tiddens HA, Sy JP, et al.: A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001, 139:813-820. This study shows that early treatment with dornase alfa can benefit patients with CF with mild lung disease. This provides evidence that early treatment might alter the disease.
20. Rosenfeld M, Gibson R, McNamara S, et al.: Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001, 139:572-577.
21. Gibson RL, Emerson J, McNamara S, et al.: Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849. Further evidence that early treatment can benefit patients with CF with early lung disease.
22. Bobadilla JL, Farrell MH, Farrell PM: Applying CFTR molecular genetics to facilitate the diagnosis of cystic fibrosis through screening. Adv Pediatr 2002, 49;131-190.
23. Bobadilla JL, Macek Jr M, Fine JP, et al.: Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002, 19:575-606. This article is a review of the known, worldwide genotypes in patients with CF.
24. Castellani C, Quinzii C, Altieri S, et al.: A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet Test 2001, 5:249-254.
25. Massie RJ, Poplawski N, Wilcken B, et al.: Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 2001, 17:1195-1200.
26. Wheeler PG, Smith R, Dorkin H, et al.: Genetic counseling after implementation of statewide cystic fibrosis newborn screening: two years' experience in one medical center. Genet Med 2001, 3:411-415. These authors report their experiences during the 2 years following initiation of a new statewide program for CF newborn screening.
27. Ciske DJ, Haavisto A, Laxova A, et al.: Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process. Pediatrics 2001, 107:699-705. These authors discuss the value of genetic counseling for newborn screening programs. This is particularly important for screening programs that include DNA testing.
28. Wilfond B, Rothenberg LS: Ethical issues in cystic fibrosis newborn screening: from data to public health policy. Curr Opin Pulm Med 2002, 8:529-534.
29. McCabe LL, Therrell BL, McCabe ER: Newborn screening: rationale for a comprehensive, fully integrated public health system. Mol Genet Metab 2002, 77:267-273.
30. Serving the family from birth to the medical home. Newborn screening: a blueprint for the future-a call for a national agenda on state newborn screening programs. Pediatrics 2000, 106(2 Pt 2):389-422. This consensus conference report on newborn screening provides comprehensive recommendations for expanding state programs.
31. Cystic Fibrosis Foundation 2000 Registry. Bethesda, MD: Cystic Fibrosis Foundation.
32. AI Kouatly HB, Chasen ST, Streltzoff J, et al.: The clinical significance of fetal echogenic bowel. Am J Obstet Gynecol 2001, 185:1035-1038.
33. MacLean Jr WC, Tripp RW: Cystic fibrosis with edema and falsely negative sweat test. J Pediatr 1973, 83:86-88.
34. Dolan Jr TF, Rowe DS, Gibson LE: Edema and hypoproteinemia in infants with cystic fibrosis. The hypoalbuminemia sometimes seen is presumably secondary to malabsorption. Olin Pediatr (Phila) 1970, 9:295-297.
35. Dolan Jr TF: Hemolytic anemia and edema as the initial signs in infants with cystic fibrosis. Consider this diagnosis even in absence of pulmonary symptoms. Clin Pediatr (Phila) 1976, 15:597-600.
36. Merelle ME, Griffioen RW, Dankert-Roelse JE: Cystic fibrosis presenting with intracerebral hemorrhage. Lancet 2001, 358:1960. This case report demonstrates the most important value of newborn screening for CF, the ability to prevent life-threatening complications of nondiagnosis.
37. Konstan MW, Butler SM, Johnson CA, et al.: The relation between nutritional status in early life and pulmonary function in cystic fibrosis. Pediatr Pulmonol Suppl 1999, 19:155-156.
38. Ranganathan SC, Dezateux C, Bush A, et al.: Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001, 358:1964-1965. This multicenter study looked at pulmonary function in infants with newly diagnosed CF. A high percentage of these conventionally diagnosed patients already had pulmonary abnormalities.
39. Farrell PM, Kosorok MR, Rock MJ, et al.: Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves longterm growth. Pediatrics 2001, 107:1-13. This article reports the 13-year outcomes from the controlled study of CF newborn screening in Wisconsin. Results show that severe malnutrition persists after delayed diagnosis and that catch-up may not be possible.
40. Macek Jr M, Macek M, Stuhrmann M, et al. The direct early diagnosis of cystic fibrosis by the detection of the delta F508 CFTR gene mutation in a prematurely delivered boy. Clin Genet 1991, 39:219-222.
41. Holmgren NL, Faro A, Gondor MI, et al.: Cystic fibrosis in three children with bronchopulmonary dysplasia. Pediatr Pulmonol 2001, 31:474-477.
42. Elphick HE, Demoncheaux EA, Ritson S, et al.: Exhaled nitric oxide is reduced in infants with cystic fibrosis. Thorax 2001, 56:151-152.
43. Wiser WC, Beier FR: Albumin in the meconium of infants with cystic fibrosis. A preliminary report. Pediatrics 1964, 33:115.
44. Crossley JR, Elliott RB, Smith PA: Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979, 1:472-474.
45. Hammond KB, Abman SH, Sokol RJ, et al.:. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med 1991, 325:769-774. Describes the first statewide CF neonatal screening program in the United States and the two-sample IRT technique for screening.
46. Newborn screening: a blueprint for the future executive summary: newborn screening task force report. Pediatrics 2000, 106(2 Pt 2):386-388.
47. Yamaguchi A, Nepote JA, Kadivar M, et al.: Allele specific PCR with microfluorometry: application to the detection of del F508 mutation in cystic fibrosis. Clin Chim Acta 2002, 316:147-154.
48. Corbetta C, Seia M, Bassotti A, et al.: Screening for cystic fibrosis in newborn infants: results of a pilot program based on a two tier protocol (IRT/DNA/IRT) in the Italian population. J Med Screen 2002, 9:60-63.
49. Scotet V, De Braekeleer M, Audrezet MP, et al.: Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis. Clin Genet 2001, 59:42-47. Cystic fibrosis newborn screening identifies infants at high risk by detecting elevated blood trypsin. This study reports a significantly higher rate of heterozygotes than expected among neonates with hypertrypsinaemia.
50. Gomez LM, Benetazzo MG, Marzari MG, et al.: High frequency of cystic fibrosis transmembrane regulator mutation L997F in patients with recurrent idiopathic pancreatitis and in newborns with hypertrypsinemia. Am J Hum Genet 2000, 66:2013-2014.
51. LeGrys VA: Sweat analysis proficiency testing for cystic fibrosis. Pediatr Pulmonol 2000, 30:476-480. This survey demonstrates large variation in sweat testing techniques between laboratories and suggests the need to review the National Committee for Clinical Laboratory 2000 Standards.
52. LeGrys VA: Assessment of sweat-testing practices for the diagnosis of cystic fibrosis. Arch Pathol Lab Med 2001, 125:1420-1424.
53. Webster HL: A critical appraisal of cystic fibrosis sweat-testing guidelines. Am Clin Lab 2001, 20:39-42.
54. Warwick WJ, Hansen LG, Brown IV, et al.: Sweat chloride: quantitative patch for collection and measurement. Clin Lab Sci 2001, 14:155-159.
55. Lai HC, Kosorok MR, Laxova A, et al.: Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening. Pediatrics 2000, 105:53-61.
56. Evans AK, Fitzgerald DA, McKay KO: The impact of meconium ileus on the clinical course of children with cystic fibrosis. Eur Respir J 2001, 18:784-789.
57. Wong U, Wang J, Zhang YH, et al.: Improved detection of CFTR mutations in Southern California Hispanic CF patients. Hum Mutat 2001, 18:296-307.
58. Heim RA, Sugarman EA, Allitto BA: Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel. Genet Med 2001, 3:168-176. This study indicates that a 50 to 70 CFTR mutation panel provides a practical test that maximizes sensitivity for screening for CF in the pan-ethnic US population.
59. Bombieri C, Pignatti PF: Cystic fibrosis mutation testing in Italy. Genet Test 2001, 5:229-233.
60. Farrell MH, Certain LK, Farrell PM: Genetic counseling and risk communication services of newborn screening programs. Arch Pediatr Adolesc Med 2001, 155:120-126.
61. Noone PG, Knowles MR: 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2001, 2:328-332. A review of the non-CF conditions possibly related to mutations of the CF gene.
62. Truninger K, Malik N, Ammann RW, et al.: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. Am J Gastroenterol 2001, 96:2657-2661.
63. Truninger K, Kock J, Wirth HP, et al.: Trypsinogen gene mutations in patients with chronic or recurrent acute pancreatitis. Pancreas 2001, 22:18-23.
64. Tzetis M, Efthymiadou A, Strofalis S, et al. CFTR gene mutations-including three novel nucleotide substitutions-and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet 2001, 108:216-221.
65. Marchand E, Verellen-Dumoulin C, Mairesse M, et al.: Frequency of cystic fibrosis transmembrane conductance regulator gene mutations and 5T allele in patients with allergic bronchopulmonary aspergillosis. Chest 2001, 119:762-767.
66. Padoan R, Bassotti A, Seia M, et al.: Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Eur J Pediatr 2002, 161:212-215.
67. Southern KW, Noone PG, Bosworth DG, et al.: A modified technique for measurement of nasal transepithelial potential difference in infants. J Pediatr 2001, 139:353-358.
68. Zeitlin PL: Advances in the diagnosis of cystic fibrosis in infants. J Pediatr 2001, 139:345-346.
69. Monaghan KG, Feldman GL, Barbarotto GM, et al.: Frequency and clinical significance of the S1235R mutation in the cystic fibrosis transmembrane conductance regulator gene: results from a collaborative study. Am J Med Genet 2000, 95:361-365.
70. Massie J, Gaskin K, Van Asperen P, et al.: Sweat testing following newborn screening for cystic fibrosis. Pediatr Pulmonol 2000, 29:452-456.
71. Wine JJ, Kuo E, Hurlock G, et al.: Comprehensive mutation screening in a cystic fibrosis center. Pediatrics 2001, 107:280-286.
72. Castellani C, Benetazzo MG, Tamanini A, et al.: Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in neonatal hypertrypsinaemia with normal sweat test. J Med Genet 2001, 38:202-205.
73. Wong L.J., Wang J, Woo M, et al.: A novel mutation detected by temporal temperature gradient gel electrophoresis led to the confirmative prenatal diagnosis of a Hispanic CF family. Prenat Diagn 2000, 20:807-810.
74. Wang J, Bowman CM, Wong LJ: A novel CFTR frame-shift mutation, 935delA, in two Hispanic cystic fibrosis patients. Mol Genet Metab 2000, 70:316-321.
75. Drumm ML: Modifier genes and variation in cystic fibrosis. Respir Res 2001, 2:125-128.
76. White SM, Lucassen A, Norbury G: Cystic fibrosis: a further case of an asymptomatic compound heterozygote. Am J Med Genet 2001, 103:342-343.
77. Farrell PM, Shen G, Splaingard M, et al.: Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997, 100:E2.
78. Wang SS, FitzSimmons SC, O'Leary LA, et al.: Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa acquisition in the first 10 years of life: A registry-based longitudinal study. Pediatrics 2001, 107:274-279.
79. Wilfond BS, Fost N: The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA 1990, 263:2777-2783. This extensive discussion of the genetic risks of CF screening points out the need for well-trained genetic counselors and a good referral system before instituting CF newborn screening.
80. Mischief EH, Wilfond BS, Fost N, et al.: Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998, 102(1 Pt 1):44-52.
81. Henneman L, Bramsen I, Van Os TA, et al.: Attitudes towards reproductive issues and carrier testing among adult patients and parents of children with cystic fibrosis CF). Prenat Diagn 2001, 21:1-9. This study assessed the reproductive choices of parents of children with CF to get a greater insight into the counseling needs of carrier couples. Most parents and adult patients with CF supported carrier identification and accepted the reproductive choices of carrier couples.
82. Gilbert F: Cystic fibrosis carrier screening: steps in the development of a mutation panel. Genet Test 2001, 5:223-227. This publication provides guidelines for developing a CF gene mutation panel specific for the population being screened.
83. Grody WW, Cutting GR, Klinger KW, et al.: Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001, 3:149-154. This is an important reference for programs developing carrier screening for CF.
84. Loader S, Caldwell P, Kozyra A, et al.: Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 1996, 59:234-247.
85. Wilson RD, Davies G, Desilets V, et al.: Cystic fibrosis carrier testing in pregnancy in Canada. J Obstet Gynaecol Can 2002, 24:644-651.
86. Delvaux I, van Tongerloo A, Messiaen L, et al.: Carrier screening for cystic fibrosis in a prenatal setting. Genet Test 2001, 5:117-125.
87. Grody WW, Desnick RJ: Cystic fibrosis population carrier screening: here at last-are we ready? Genet Med 2001, 3:87-90.
88. Koletzko S, Reinhardt D: Nutritional challenges of infants with cystic fibrosis. Early Hum Dev 2001, 65(suppl):S53-S61. This is an excellent review of the special nutritional needs of infants with CF.
89. Abman SH, Reardon MC, Accurso FJ, et al.: Hypoalbuminemia at diagnosis as a marker for severe respiratory course in infants with cystic fibrosis identified by newborn screening. J Pediatr 1985, 107:933-935. Even with newborn screening, infants with CF are at risk for malnutrition and severe respiratory infections. This article reports an association between hypoalbuminemia and early, severe respiratory complications.
90. Bines JE, Truby HD, Armstrong DS, et al.: Energy metabolism in infants with cystic fibrosis. J Pediatr 2002, 140:527-533.
91. Davies PS, Erskine JM, Hambidge KM, et al.: Longitudinal investigation of energy expenditure in infants with cystic fibrosis. Eur J Clin Nutr 2002, 56:940-946.
92. Bronstein MN, Sokol RJ, Abman SH, et al.: Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992, 120(4 Pt 1):533-40. Results from this well-conducted study show that infants develop worsening pancreatic insufficiency during the first year of life. Close monitoring of nutritional state is necessary to detect the early signs of malabsorption so that therapy can be started.
93. Stapleton D, Kerr D, Gurrin L, et al.: Height and weight fail to detect early signs of malnutrition in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2001, 33:319-325. This study further supports the need for close follow-up of patients with CF in specialized care centers where nutritional expertise is available.
94. Carroccio A, Verghi F, Santini B, et al. Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Italian Society of Pediatric Gastroenterology and Hepatology. Dig Dis Sci 2001, 46:1335-1342.
95. Van den Neucker AM, Kerkvliet EM, Theunissen PM, et al.: Acid steatocrit: a reliable screening tool for steatorrhoea. Acta Paediatr 2001, 90:873-875.
96. Mizejewski GJ, Pass KA: Fatty acids, alpha-fetoprotein, and cystic fibrosis. Pediatrics 2001, 108:1370-1373.
97. Krebs NF, Westcott JE, Arnold TD, et al.: Abnormalities in zinc homeostasis in young infants with cystic fibrosis. Pediatr Res 2000, 48:256-261.
98. Soltani-Frisk S, Gronowitz E, Andersson H, et al.: Water-miscible tocopherol is not superior to fat-soluble preparation for vitamin E absorption in cystic fibrosis. Acta Paediatr 2001, 90:1112-1115.
99. Wilson DC, Rashid M, Dude PR, et al.: Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination. J Pediatr 2001, 138:851-855.
100. Scher H, Bishop WP, McCray Jr PB:. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis. Ann Pharmacother 1997, 31:1003-1005.
101. Wood LG, Fitzgerald DA, Gibson PG, et al.: Oxidative stress in cystic fibrosis: dietary and metabolic factors. J Am Coll Nutr 2001, 20(2 Suppl):157-165.
102. Rosenfeld M, Gibson RL, McNamara S, et al.: Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001, 32:356-366. This is an excellent study monitoring the earliest changes in the lungs of infants with CF. Bacterial pathogens and neutrophilic inflammation are identified in symptomatic, as well as asymptomatic infants.
103. Gutierrez JP, Grimwood K, Armstrong DS, et al.: Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001, 17:281-286.
104. Smyth A, Walters S: Prophylactic antibiotics for cystic fibrosis (Cochrane Review). Cochrane Database Syst Rev 2001, 3:CD001912.
105. Ratjen F, Comes G, Paul K, et al.: Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001, 31:13-16.
106. Burns JL, Gibson RL, McNamara S, et al.: Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001, 183:444-452. Pseudomonas aeruginosa is an important pathogen in CF. These authors followed children for 3 years and identified that bacteria changed over time, suggesting therapy could alter early colonization and infection.
107. Kosorok MR, Zeng L, West SE, et al.: Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32:277-287.
108. Nixon GM, Armstrong DS, Carzino R, et al.: Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001, 138:699-704.
109. Ratjen F, Doring G, Nikolaizik WH: Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Lancet 2001, 358:983-984. This study shows that inhaled tobramycin is effective in eradicating Pseudomonas aeruginosa from the airways of children with CF when the treatment is applied early.
110. Wojtczak HA, Kerby GS, Wagener JS, et al.: Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2001, 32:293-302.
111. Equi AC, Pike SE, Davies J, et al.: Use of cough swabs in a cystic fibrosis clinic. Arch Dis Child 2001, 85:438-439.
112. Gappa M, Ranganathan SC, Stocks J: Lung function testing in infants with cystic fibrosis: lessons from the past and future directions. Pediatr Pulmonol 2001, 32:228-245. These authors review infant pulmonary function testing techniques and their value in patients with CF.
113. Davis S, Jones M, Kisling J, et al.: Comparison of normal infants and infants with cystic fibrosis using forced expiratory flows breathing air and heliox. Pediatr Pulmonol 2001, 31:17-23.
114. Doull IJ: Recent advances in cystic fibrosis. Arch Dis Child 2001, 85:62-66.
115. Orenstein DM, Winnie GB, Altman H: Cystic fibrosis: a 2002 update. J Pediatr 2002, 140:156-164. This article is a superb review of current clinical care for patients with CF.
116. Padoan R, Genoni S, Moretti E, et al.: Genetic and clinical features of falsenegative infants in a neonatal screening program for cystic fibrosis. Acta Paediatr 2002, 91:82-87.